Octreotide Intramuscular Injection Kits Shortage
Last Updated: June 4, 2025
Status: Current
Products Affected - Description
-
- Octreotide Acetate intramuscular injection, Teva, 10 mg, kit, 1 count, NDC 00480-9257-08
- Octreotide Acetate intramuscular injection, Teva, 20 mg, kit, 1 count, NDC 00480-9259-08
- Octreotide Acetate intramuscular injection, Teva, 30 mg, kit, 1 count, NDC 00480-9262-08
Reason for the Shortage
-
- Novartis has Sandostatin LAR intramuscular injection available.
- Teva did not provide a reason for the shortage.
Available Products
-
- Sandostatin LAR Depot intramuscular injection, Novartis, 10 mg, kit, 1 count, NDC 00078-0811-81
- Sandostatin LAR Depot intramuscular injection, Novartis, 20 mg, kit, 1 count, NDC 00078-0818-81
- Sandostatin LAR Depot intramuscular injection, Novartis, 30 mg, kit, 1 count, NDC 00078-0825-81
Estimated Resupply Dates
-
- Teva has octreotide 10 mg kits for intramuscular injection on back order and the company estimates a release date in mid-June 2025. The 20 mg and 30 mg kits are on back order and the company estimates a release date of late-June 2025.
Updated
Created June 4, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.